Author: Ken Dropiewski

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Approval marks second clinical trial approved by FDA this year for Company’s NK1R+ MSC platform Allogeneic CardiALLO therapy for heart failure to complement autologous cell therapy currently enrolling in Phase III CardiAMP Heart Failure clinical trial SUNNYVALE, Calif.–(BUSINESS WIRE)–BioCardia, Inc. [Nasdaq: BCDA], […]

Medtronic completes enrollment in pivotal trial evaluating first-of-its-kind pulsed field ablation catheter for patients with atrial fibrillation

SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN, Dec. 5, 2022 /PRNewswire/ — Medtronic (NYSE:MDT) today announced the completion of enrollment and final treatment in the […]

Mindray Introduces New Wearable Patient Monitoring System, Refining Clinician’s Workflow to Track Patient Conditions

SHENZHEN, China–(BUSINESS WIRE)–Mindray (SZSE: 300760), a global leader in providing advanced medical device solutions, today launches the mWear™ system, an all-new wearable patient monitoring solution that enables an efficient workflow to continually monitor patient conditions and deliver patient-centric care. With […]

Rhythm Management Group Announces Acquisition of Equis Consulting Group

Acquisition creates one of the largest remote cardiac monitoring service providers in the nation. ROCKVILLE, Md., Dec. 5, 2022 /PRNewswire/ — Rhythm Management Group (Rhythm) has announced the acquisition of Equis Consulting Group (Equis), an Indiana-based provider of clinical and consultative remote monitoring and management services. The acquisition, […]

Acticor Biotech Receives European Medicines Agency (EMA) Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke

Approval of ACTISAVE design by the EMA to support a potential future marketing authorization application (MAA) for glenzocimab in Stroke Validation du choix d’un double critère d’évaluation principal : – Échelle de Rankin modifiée (mRS)1 – Échec (versus succès) défini par un […]